Vous avez cherché: nelarabine (Maltais - Anglais)

nelarabine
nelarabine

kull ml fih 5 mg ta 'nelarabine.
each ml contains 5 mg of nelarabine.

kull fjala fiha 250 mg ta 'nelarabine.
each vial contains 250 mg of nelarabine.

is-sustanza attiva ta' atriance huwa nelarabine.
the active substance of atriance is nelarabine.

nelarabine u ara-g jitneħħew parzjalment mill-kliewi.
nelarabine and ara-g are partially eliminated by the kidneys.

atriance 5 mg/ml soluzzjoni għall-infużjoni nelarabine
atriance 5 mg/ml solution for infusion nelarabine

ma sarux testijiet dwar il- karċinoġeniċita 'ta' nelarabine.
carcinogenicity testing of nelarabine has not been performed.

Ġew irrappurtati reazzjonijiet avversi newroloġiċi serji meta ntuża nelarabine.
severe neurological reactions have been reported with the use of nelarabine.

ma hemm l- ebda antidot magħruf għal doża eċċessiva ta 'nelarabine.
8 there is no known antidote for nelarabine overdose.

mekkaniżmi oħra jistgħu jikkontribwixxu għall- effetti ċitotossiċi ta 'nelarabine.
other mechanisms may contribute to the cytotoxic effects of nelarabine.

mhux dejjem kien hemm fejqan totali minn dawn ir-reazzjonijiet meta twaqqaf nelarabine.
full recovery from these reactions has not always occurred with cessation of nelarabine.

ma hemmx biżżejjed tagħrif dwar l- użu ta 'nelarabine f' nisa tqal.
there are no adequate data from the use of nelarabine in pregnant women.

in- newrotossiċita 'hija t- tossiċita li tillimita d- doża ta' nelarabine.
3 neurotoxicity is the dose-limiting toxicity of nelarabine.

it- tneħħija ta 'nelarabine fil- ħalib ma ġietx studjata f' annimali.
the excretion of nelarabine in milk has not been studied in animals.

madankollu huwa magħruf li nelarabine huwa ġenotossiku għal ċelluli mammiferi (ara sezzjoni 5.3).
nelarabine however, is known to be genotoxic to mammalian cells (see section 5.3).

barra minn hekk, parti minn nelarabine jiġi idrolizzat għal methylguanine, li jiġi o-demetilizzat biex jifforma guanine.
in addition, some nelarabine is hydrolysed to form methylguanine, which is o-demethylated to form guanine.

meta jingħataw nelarabine pazjenti b'indeboliment tal-kliewi għandhom jiġu segwiti mill-qrib għal tossiċitajiet.
patients with renal impairment must be closely monitored for toxicities when treated with nelarabine.

ir-reazzjonijiet avversi li ġejjin ġew identifikati waqt l-użu wara l-approvazzjoni ta’ nelarabine.
the following adverse reactions have been identified during post-approval use of nelarabine.

4 mhuwiex rakkomandat l- użu ta 'nelarabine flimkien ma' inibituri ta 'adenosine deaminase bħal pentostatin.
4 4.6 pregnancy and lactation

l-effett tar-razza fuq il-farmakokinetika ta' nelarabine u ara-g ma ġiex studjat speċifikament.
the effect of race on nelarabine and ara-g pharmacokinetics has not been specifically studied.